Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
gs-441524
- Development stage
- Phase 1
- Lead developer
- Gilead Sciences
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Administration
- Oral, Subcutaneous
01
Overview
GS-441524 is a nucleoside analogue antiviral drug developed by Gilead Sciences. It functions as the main plasma metabolite of the antiviral prodrug remdesivir, with a half-life of approximately 24 hours in humans. The drug works by undergoing intracellular triple-phosphorylation to yield its active form, which disrupts viral RNA replication by competing with endogenous NTPs and triggering delayed chain termination of RNA-dependent RNA polymerase. GS-441524 has demonstrated remarkable effectiveness in treating feline infectious peritonitis (FIP), a previously fatal disease in cats, and has also been investigated for potential use against Ebola and SARS-CoV-2 infections.
- Other names
- 1191237-69-01BQK176DT6UNII-1BQK176DT6UNII1BQK176DT6UNII 1BQK176DT6CHEBI:147281(2R,3R,4S,5R)-2-(4-Aminopyrrolo(2,1-f)(1,2,4)triazin-7-yl)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydro-2-furancarbonitrile2-C-(4-Aminopyrrolo(2,1-f)(1,2,4)triazin-7-yl)-2,5-anhydro-D-altrononitrileD-Altrononitrile, 2-C-(4-aminopyrrolo(2,1-f)(1,2,4)triazin-7-yl)-2,5-anhydro-
02
Targets
RdRp (Coronavirus RNA-dependent RNA polymerase)
Beyond the preview
Go deeper on gs-441524.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on gs-441524.